Sarepta Therapeutics (SRPT) volatility pulls back on sharp rally on FDA approval
Get instant alerts when news breaks on your stocks. Claim your 2-week free trial to StreetInsider Premium here.
Sarepta Therapeutics (NASDAQ: SRPT) is recently up $2.05 to $50.99 in the premarket after saying it sees the U.S. annual cost of eteplirsen at $300,000, a day after rallying 73% on the FDA approval of eteplirsen. September weekly call option implied volatility is at 145, October is at 88; compared to its 52-week range of 79 to 399.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Stocks with Implied Volatility Movement
- Stocks with call strike movement; DB NFLX
- IPath S&P 500 VIX Short-Term Futures (VXX) up 9c to 35.73
Create E-mail Alert Related CategoriesOptions, Trader Talk
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!